Table 4. Metastatic compromise of non-SLN, percent of modification to phase pN2 and pN3, in patients with MAM,according to clinicopathologic subtype and tumour size (n = 140 patients).

			Phase N post ALND
Phase N pre ALND	With ALND	nonSLN +	pN1a	pN2	pN3	% modification	p*
LUMINAL	125	56	26	24	6	24.2	…
Tu ≤ 2 cm	53	27	17	8	2	17.0
Tu > 2 cm	72	30	9	18	4	29.2	0.15
NO LUMINAL	15	8	3	3	2	33.3	0.44
Tu ≤ 2 cm	9	5	3	1	1	22.2
Tu > 2 cm	6	3	0	2	1	50.0	0.26

non-SLN: non sentinel lymph node,

MAM: macrometastasis,

ALND: axillary lymph node dissection.

^*p value calculated based on chi-square test.